bioAffinity Technologies, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that bioAffinity Technologies, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $7.90M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $6.90M | Apr 1, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.16M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $9.36M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $2.53M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.8K | Apr 1, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $4.3K | Mar 31, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.91M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($9.04M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($7.94M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($8.15M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($6.33M) | Mar 31, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.57M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($8.95M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($7.97M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($4.01M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($2.21M) | Mar 31, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.38M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $1.46M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $1.47M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.38M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.01M | Mar 31, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.91M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $9.94M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $6.79M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.48M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.07M | Mar 31, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.33M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($7.26M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($6.04M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($4.07M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($2.05M) | Mar 31, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.6K | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $79.1K | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $22.9K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $220.0K | Apr 1, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.96M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $6.51M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $8.22M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $12.18M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.45M | Mar 31, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.68M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $3.91M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $3.37M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.14M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $13.20M | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.28M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $2.60M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $4.86M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $11.04M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($15.79M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | ($15.07M) | Mar 31, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.40M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $1.40M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $1.40M | Mar 31, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($68.55M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($53.64M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($44.60M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($36.67M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($28.51M) | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.45M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $1.11M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $2.82M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.41M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.36M | Mar 31, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (22) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (22) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.50M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 519,158 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 9.39M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 8.38M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 2.68M | Mar 31, 2023 |